Radiation oncology (London, England) · 2025
Outcomes and recurrence pattern analysis of intensity modulated chemoradiotherapy in nasopharyngeal cancer: a retrospective study from Heidelberg University Hospital.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bauer Lukas, Regnery Sebastian, Deng Maximilian Y, Stritzke Florian, Schröter Philipp, Franke Henrik, Netzer Nils B, Uzun-Lang Kristin, Weusthof Katharina, Thoelken Rubens, Debus Jürgen, Held Thomas
Аннотация
BACKGROUND: To evaluate treatment outcomes, toxicity, and recurrence patterns by dose level in nasopharyngeal carcinoma (NPC) patients treated with intensity-modulated radiotherapy (IMRT) and weekly cisplatin.
METHODS: We retrospectively analyzed 48 NPC patients treated between 2005 and 2019 with IMRT and weekly cisplatin (40 mg/m²). The planning target volume (PTV) received a median total dose of 57.6 Gy (1.8 Gy/fraction) with a simultaneous integrated boost to the primary tumor and nodal metastases up to 70.4 Gy. To assess recurrence patterns, follow-up imaging was deformably co-registered with planning CTs (pCT), and recurrent gross tumor volumes (rGTVs) were delineated and mapped to pCTs. Recurrences were categorized using a centroid-based system into five types: A (central high-dose), B (peripheral high-dose), C (central intermediate-/low-dose), D (peripheral intermediate-/low-dose), and E (extraneous dose).
RESULTS: With a median follow-up of 73 months (range 24-156), 9 patients (19%) had died. The 3-, 5-, and 10-year overall survival rates were 98%, 96%, and 67%, respectively. Local control rates (LCR) at 2, 3, and 5 years were 92%, 89%, and 89%; regional control was 96%, 94%, and 94%; and distant control was 92%, 89%, and 89%. Treatment was well tolerated, with no grade ≥ 4 toxicities. Grade 3 acute toxicities occurred in 23 patients (48%), most commonly dysphagia, with nearly all resolving within 90 days. Among treatment failures, distant metastases (13%) and local relapses (10%) were most frequent. Of 8 local and/or regional recurrences analyzed, 2 were type A (central high-dose), 3 type B ("marginal"), 2 type C (central intermediate-/low-dose), and 1 type E ("out-of-field").
CONCLUSION: IMRT with weekly cisplatin yields excellent survival and locoregional control with acceptable toxicity in NPC. Distant metastasis as one of the predominant failure patterns highlights the need for more effective systemic therapies. Most local recurrences arose within high-dose areas, suggesting a potential opportunity for treatment optimization.
METHODS: We retrospectively analyzed 48 NPC patients treated between 2005 and 2019 with IMRT and weekly cisplatin (40 mg/m²). The planning target volume (PTV) received a median total dose of 57.6 Gy (1.8 Gy/fraction) with a simultaneous integrated boost to the primary tumor and nodal metastases up to 70.4 Gy. To assess recurrence patterns, follow-up imaging was deformably co-registered with planning CTs (pCT), and recurrent gross tumor volumes (rGTVs) were delineated and mapped to pCTs. Recurrences were categorized using a centroid-based system into five types: A (central high-dose), B (peripheral high-dose), C (central intermediate-/low-dose), D (peripheral intermediate-/low-dose), and E (extraneous dose).
RESULTS: With a median follow-up of 73 months (range 24-156), 9 patients (19%) had died. The 3-, 5-, and 10-year overall survival rates were 98%, 96%, and 67%, respectively. Local control rates (LCR) at 2, 3, and 5 years were 92%, 89%, and 89%; regional control was 96%, 94%, and 94%; and distant control was 92%, 89%, and 89%. Treatment was well tolerated, with no grade ≥ 4 toxicities. Grade 3 acute toxicities occurred in 23 patients (48%), most commonly dysphagia, with nearly all resolving within 90 days. Among treatment failures, distant metastases (13%) and local relapses (10%) were most frequent. Of 8 local and/or regional recurrences analyzed, 2 were type A (central high-dose), 3 type B ("marginal"), 2 type C (central intermediate-/low-dose), and 1 type E ("out-of-field").
CONCLUSION: IMRT with weekly cisplatin yields excellent survival and locoregional control with acceptable toxicity in NPC. Distant metastasis as one of the predominant failure patterns highlights the need for more effective systemic therapies. Most local recurrences arose within high-dose areas, suggesting a potential opportunity for treatment optimization.
Предметные рубрики MeSH
HumansRetrospective StudiesRadiotherapy, Intensity-ModulatedMaleFemaleMiddle AgedChemoradiotherapyAdultNeoplasm Recurrence, LocalNasopharyngeal NeoplasmsAgedCisplatinNasopharyngeal CarcinomaRadiotherapy DosageHospitals, UniversityYoung AdultSurvival RateFollow-Up StudiesRadiotherapy Planning, Computer-AssistedPrognosis